Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) publishes its year-end report for the period January - December 2024. The report is available on ...

Phase 3 topline data from azetukalner FOS epilepsy program planned for H2 2025 in support of NDA filing and potential commercial launch - First of three planned Phase 3 azetukalner MDD studies underwa ...

Phase 3 topline data from azetukalner FOS epilepsy program planned for H2 2025 in support of NDA filing and potential commercial launch– First ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

A higher comorbidity burden was linked to an increased rate of adverse events as well as early discontinuation among patients ...

Clene will join APST Research to explore how CNM-Au8 affects NfL levels in ALS patients treated in expanded access programs.

At 2 years, participants in the compensated MASH cirrhosis treatment arm of the MAESTRO-NAFLD-1 trial experienced a ...

Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET. Company Participants. Katie Hogan - Senior Director-Corporate Communications and Investo ...

Five years later, and in the face of a potentially changing healthcare landscape again, Dr. Lynch is ever committed and steadfast in his vision for the NCI-designated cancer center. He recently shared ...

Regarding patients with HER2-negative, estrogen receptor (ER)-positive breast cancer, the phase 3 KEYNOTE-756 study is ...